To assess the therapeutic activity of CpG-M-miR-142 in combination with TKI in vivo, we generated a disease-synchronized cohort of BC CML mice by transplanting 106 BM MNCs from diseased miR-142−/−BCR-ABL mice (CD45.2) into congenic wt recipient mice (CD45.1). Here, ABL1 is linked to breast cancer.